Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Total Current Liabilities (2018 - 2025)

Historic Total Current Liabilities for Neurogene (NGNE) over the last 6 years, with Q3 2025 value amounting to $14.7 million.

  • Neurogene's Total Current Liabilities fell 689.87% to $14.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.7 million, marking a year-over-year decrease of 689.87%. This contributed to the annual value of $15.2 million for FY2024, which is 3402.25% down from last year.
  • According to the latest figures from Q3 2025, Neurogene's Total Current Liabilities is $14.7 million, which was down 689.87% from $15.4 million recorded in Q2 2025.
  • In the past 5 years, Neurogene's Total Current Liabilities registered a high of $23.0 million during Q4 2023, and its lowest value of $4.9 million during Q2 2023.
  • For the 3-year period, Neurogene's Total Current Liabilities averaged around $12.8 million, with its median value being $14.1 million (2025).
  • Within the past 5 years, the most significant YoY rise in Neurogene's Total Current Liabilities was 20314.66% (2024), while the steepest drop was 3402.25% (2024).
  • Neurogene's Total Current Liabilities (Quarter) stood at $23.0 million in 2023, then crashed by 34.02% to $15.2 million in 2024, then decreased by 2.95% to $14.7 million in 2025.
  • Its Total Current Liabilities stands at $14.7 million for Q3 2025, versus $15.4 million for Q2 2025 and $14.1 million for Q1 2025.